ArticleWiener klinische Wochenschrift2022
Higher serum uric acid is associated with higher risks of thrombosis and death in patients with primary myelofibrosis.
Article in Wiener klinische Wochenschrift, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 16 citations in OpenAlex.
- Symptomatic Osteoarthritis May Be Associated with Higher Symptom Burden and Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Prospective Two-Centre Study.Journal of clinical medicine · 2026Article
- Severe tophaceous gout in the setting of myelofibrosis: A clinical challenge.Radiology case reports · 2026Article
- Hyperuricemia is a prognostic marker for antiphospholipid syndrome patients: a retrospective cohort study in China.Clinical rheumatology · 2025Article
- Association between uric acid-albumin ratio and spontaneous reperfusion in ST-segment elevation myocardial infarction patients.Journal of geriatric cardiology : JGC · 2025Article
- The impact of inflammatory factors on patients with concurrent lung cancer and acute pulmonary embolism.Frontiers in cardiovascular medicine · 2025Article
- Sex Differences in Patients with Heart Failure with Reduced Ejection Fraction Combined with Anemia and Hyperuricemia: A Retrospective Case Study.International journal of general medicine · 2025Article
- Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives.Annals of hematology · 2024Review
- Targeted Metabolomics Highlights Dramatic Antioxidant Depletion, Increased Oxidative/Nitrosative Stress and Altered Purine and Pyrimidine Concentrations in Serum of Primary Myelofibrosis Patients.Antioxidants (Basel, Switzerland) · 2024Article
- A nomogram to predict ventricular thrombus in dilated cardiomyopathy patients.Journal of thrombosis and thrombolysis · 2024Article
- A Mendelian randomization study of serum uric acid with the risk of venous thromboembolism.Arthritis research & therapy · 2023Article
- Hip and Knee Osteoarthritis in Patients with Chronic Myeloproliferative Neoplasms: A Cross-Sectional Study.Life (Basel, Switzerland) · 2023Article
- Polypharmacy, Potentially Inappropriate Medications, and Drug-to-Drug Interactions in Patients with Chronic Myeloproliferative Neoplasms.Biomedicines · 2023Article
- Primary Arterial Hypertension and Drug-Induced Hypertension in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review.Biomedicines · 2023Review
- The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms.European heart journal · 2021Article
- Uric Acid-An Emergent Risk Marker for Thrombosis?Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSerum uric acid (SUA) can promote inflammation and is associated with increased cardiovascular morbidity. Primary (PMF) and secondary myelofibrosis (SMF) are myeloproliferative neoplasms characterized by high cellular turnover and substantial risk of thrombosis and death.
methodsWe have retrospectively investigated SUA in 173 patients with myelofibrosis (125 PMF; 48 SMF) and 30 controls.
resultsThe PMF patients had significantly higher SUA in comparison to SMF and controls. In both PMF and SMF higher SUA was significantly associated with arterial hypertension and decreased renal function. Among PMF patients, higher SUA was significantly associated with older age, larger spleen, higher white blood cell counts, higher lactate dehydrogenase, lower immunoglobulin G levels, allopurinol use and non-smoking. Among SMF patients, higher SUA was associated with male sex (P < 0.05 for all analyses). In PMF higher SUA was univariately associated with inferior survival (> 427 μmol/L hazard ratio (HR) = 2.22; P = 0.006) and shorter time to thrombosis (> 444 μmol/L HR = 5.05; P = 0.006), which could be shown separately for arterial (> 380 μmol/L; HR = 4.9; P = 0.013) and venous thromboses (> 530 μmol/L; HR = 17.9; P < 0.001). In multivariate analyses, SUA remained significantly associated with inferior survival independent of the Dynamic International Prognostic Staging System and with shorter time to thrombosis independent of age in PMF patients; however, the prognostic significance of SUA was diminished after including serum creatinine in the models. SUA was not prognostic in SMF patients.
conclusionThe PMF patients present with higher SUA levels, which are associated with features of more advanced disease and higher risks of arterial and venous thrombosis and death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.